Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rSIFN-co in Combination With Total Neo-adjuvant Therapy in Mid-low Locally Advanced Rectal Cancer
NCT07662278Phase 2Not yet recruiting
- Sponsor
- Sichuan Huiyang Life Engineering
- Start
- Jan 2027
- Primary completion
- Jan 2030
01
Overview
A Phase 2 trial of recombinant super-compound interferon in rectal cancer, sponsored by Sichuan Huiyang Life Engineering. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
recombinant super-compound interferon
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07662278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662278.